Measuring Blood Flow in Kidney Tumors with PET
Author Information
Author(s): Anderson H, Yap J T, Wells P, Miller M P, Propper D, Price P, Harris A L
Primary Institution: Cancer Research UK PET Oncology Group, Imperial College School of Medicine
Hypothesis
Following treatment with razoxane, there would be a reduction in perfusion, VD, and BV of tumors as the hyperaemic and abnormal vascular channels are replaced by fewer normal vessels.
Conclusion
The study found no statistically significant change in vascular parameters after treatment with razoxane in patients with renal cell carcinoma.
Supporting Evidence
- 12 patients were enrolled in the study, but only 7 had scans before and after treatment.
- Two out of six patients showed a reduction in perfusion after treatment, but it was not statistically significant.
- The mean pretreatment perfusion was 0.81 ml/min/ml, and post-treatment it was 0.72 ml/min/ml.
Takeaway
Doctors used a special scan to see how blood flows in kidney tumors before and after giving a medicine called razoxane, but they didn't find any big changes.
Methodology
Patients were scanned before and after treatment with razoxane using positron emission tomography to measure blood flow and volume in tumors.
Potential Biases
Potential bias due to the small number of patients who completed both scans.
Limitations
The small sample size and lack of control data limit the conclusions that can be drawn from this study.
Participant Demographics
Patients with renal tumors, including both primary and metastatic cases.
Statistical Information
P-Value
0.15
Statistical Significance
p=0.15
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website